Clinical trial
A Prospective, Single-Center, Single-Arm Study to Evaluate the Efficacy and Safety of Liposomal Irinotecan, Vincristine, and Temozolomide With or Without Anlotinib in Children and Adolescents With Relapsed or Refractory Malignant Solid Tumors
NCT07444918 is registered in ClinicalTrials.gov with Tianjin Medical University Cancer Institute and Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Prospective, Single-Center, Single-Arm Study to Evaluate the Efficacy and Safety of Liposomal Irinotecan, Vincristine, and Temozolomide With or Without Anlotinib in Children and Adolescents With Relapsed or Refractory Malignant Solid Tumors
- Lead sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Phase
- Phase 2
- Overall status
- Not yet recruiting
- Start date
- March 1, 2026
- Completion date
- June 6, 2032
- Enrollment
- 33 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
relapsed or refractory pediatric malignant solid tumors (including neuroblastoma, rhabdomyosarcoma, ewing sarcoma, osteosarcoma)